Oramed Pharmaceuticals (NASDAQ: ORMP) net income
Oramed Pharmaceuticals reported a net profit of $64.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $19.1m. Its net margin was 3,202.5%. Earnings per share were $1.53.
Fiscal 2025 is the highest of the 10 fiscal years on record for Oramed Pharmaceuticals. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $64.1m | — | 3,202.5% | $1.53 |
| 2024 | −$19.1m | −474.6% | — | −$0.48 |
| 2023 | $5.1m | — | 379.7% | $0.14 |
| 2022 | −$36.6m | — | −1,352.6% | −$0.94 |
| 2021 | −$23.0m | — | −850.5% | — |
| 2020 | −$11.5m | — | −424.8% | — |
| 2019 | −$14.4m | — | −531.1% | — |
| 2018 | −$12.7m | — | −519.7% | — |
| 2017 | −$10.5m | — | −426.7% | — |
| 2016 | −$11.0m | — | −1,710.5% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Oramed Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Oramed Pharmaceuticals ranks 126th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Oramed Pharmaceuticals, 3,202.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 124th | UFP Technologies | $68.3m | 11.3% |
| 125th | Veracyte | $66.4m | 12.8% |
| 126th | Oramed Pharmaceuticals | $64.1m | 3,202.5% |
| 127th | Collegium Pharmaceutical | $62.9m | 8.1% |
| 128th | Healthcare Services Group | $59.1m | 3.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Oramed Pharmaceuticals
- How much did Oramed Pharmaceuticals earn in fiscal 2025?
- Oramed Pharmaceuticals reported a net profit of $64.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $19.1m.
- What are the earnings per share of Oramed Pharmaceuticals?
- They were $1.53 in fiscal 2025, compared with −$0.48 in fiscal 2024.
- What is the net margin of Oramed Pharmaceuticals?
- In fiscal 2025 its net profit was 3,202.5% of its revenue.
- What was the most profitable year for Oramed Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $64.1m.
- Where does Oramed Pharmaceuticals rank in its sector by net income?
- It ranks 126th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Oramed Pharmaceuticals come from?
- From the annual report (Form 10-K) that Oramed Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Oramed Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Oramed Pharmaceuticals: the Oramed Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.